Taken together, these findings suggest that there is a correlation between the magnitude of the early effector response and overall in vivo efficacy, and underscore the therapeutic potential of ATG5 deletion as a strategy to improve CAR-T outcomes in ovarian cancer. Here, ATG5 is linked to ovarian cancer.